Personalized Medicine in Patients With Infective Endocarditis
NCT ID: NCT04838938
Last Updated: 2023-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2021-03-01
2023-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Furthemore, metagenomic sequencing may be a helpful supplement to IE diagnostic, especially when conventional tests fail to yield a diagnosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Etiology of Endocarditis in Negative Blood Cultures
NCT02816307
Characterization of Enterococcus Faecalis Endocarditis and Impact of Amoxicillin MIC Elevation on Patient Outcome
NCT05530837
Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes in Infective Endocaridtis
NCT02466139
Impact of the Blood Culture Technique on the Diagnosis of Infective Endocarditis
NCT03153384
The Role of Polymerase Chain Reaction in the Management of Patients With Infective Endocarditis
NCT05791357
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The clinical variability, including the heterogeneous response to infection and the different antibiotic treatments make the identification of the underlying pathogens of infective endocarditis (IE) is critical for precision therapy. Virulence factors mediate tissue adherence, host infiltration, immune resistance/evasion, and dynamic stress responses and confer enhanced pathogen survival, proliferation, and host invasion in animal models of infective endocarditis.
To identify the microorganism and simultaneously considered the response of the host to the infection could improve the management of the infective endocarditis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación para la Investigación Biosanitaria del Principado de Asturias
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guillermo Muñiz Albaiceta, MD, PhD
Role: STUDY_DIRECTOR
HUCA-FINBA, Universidad de Oviedo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FINBA_critlab_4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.